Happy Friday! Big news for patients and affordability in the biosimilar space! * Adalimumab biosimilar (Cyltezo): BI and GoodRx are teaming up to offer this medication for autoimmune diseases at a much lower cost! *Ustekinumab biosimilar (Uzpruvo): European patients with Crohn's disease, psoriatic arthritis, and plaque psoriasis now have a new option! 🇪🇺 *Bevacizumab biosimilar (Bhava): Mexico just approved a new biosimilar treatment for various cancers 🇲🇽 https://lnkd.in/euZcTSns
The Center for Biosimilars
Book and Periodical Publishing
Cranbury, NJ 16,039 followers
The authoritative resource for emerging therapies.
About us
Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.
- Website
-
http://www.centerforbiosimilars.com
External link for The Center for Biosimilars
- Industry
- Book and Periodical Publishing
- Company size
- 2-10 employees
- Headquarters
- Cranbury, NJ
- Type
- Privately Held
- Founded
- 2016
- Specialties
- biosimilars, biosimilar news, pharmaceuticals, policy, regulatory, and clinical
Locations
-
Primary
-
Cranbury, NJ 08512, US
Employees at The Center for Biosimilars
Updates
-
Did you know that around half of people in EU with rheumatic diseases stayed on a biosimilar medication after a year? The study looked at patients who switched from the original medication to a biosimilar. Interestingly, some patients switched back even though the medications should work the same way! This might be due to the nocebo effect, where negative feelings about a medication can cause adverse effects🧠 Want to learn more about biosimilars and the nocebo effect? Check out the full article here: https://lnkd.in/emccGPzw
-
-
Join us as we discuss the US biosimilars market! What are the key factors impacting their adoption in the US? In this episode of Not So Different, we explore: ** The current legislative and regulatory environment for biosimilars ** Economic considerations, clinical evidence, and market dynamics affecting payer and provider decisions ** Challenges and opportunities for manufacturers, payers, providers, and patients Listen now and learn how biosimilars can make a positive impact on our health care system. https://lnkd.in/e5F6p7JZ
-
The FDA just approved eculizumab-aagh (Epysqli), a new treatment option for PNH and aHUS, from Samsung Bioepis. This marks the second biosimilar to eculizumab (Soliris) and Samsung Bioepis' 8th biosimilar approval in the US! Want to learn more? Head over to our website for all the details on eculizumab-aagh and the growing biosimilars market: Don't forget to check out the approvals tab to see all of the biosimilars that have been approved! https://lnkd.in/eNN7DPiK
-
-
Saving Money for Hospitals, But What About Patient Care? Biosimilars are supposed to lower drug costs, but a new study asks if that translates to more hospital visits or longer stays. This research looked at a specific biosimilar and found no increase in resource use, but further studies are needed. Read the full article to learn more: https://lnkd.in/eBai5p9f
-
Half of Patients May Not Fully Grasp Biosimilar Switch: A new study found that over half of patients with chronic inflammatory diseases who switched to a biosimilar medication may have had difficulty understanding the information they received. This could impact their satisfaction with the switch. Good communication is key! Read on to learn how to ensure patients understand biosimilars and feel confident in their treatment plan. https://lnkd.in/eAfbMkFa
Approximately Half of Patients Demonstrated Poor Health Literacy Prior to Biosimilar Switch
centerforbiosimilars.com
-
Biosimilars news you need to know! This week's top articles: 5. An expert discusses how biosimilars can deliver high-quality care while reducing costs 4. Study finds biosimilar trastuzumab-dkst offers similar experiences to Herceptin for HER2+ breast cancer 3. Biosimilar DMARDs show promise for patients with RA who don't respond to methotrexate 2. Big Biosimilar Week: EU approves new biosimilar, US sees launch, and switching data for a denosumab biosimilar 1. Fixing the System: Expert discusses challenges with PBMs hindering biosimilar use, and new legislation aiming to improve access Click the link to watch the full video: https://lnkd.in/eGahSEnB
The Top 5 Biosimilar Articles for the Week of July 15
centerforbiosimilars.com
-
Big changes for biosimilars in the Middle East? The WHO's new guidelines could save money and speed up approvals, but there's a catch. Is the Middle East ready? Find out why some countries are hesitant: https://lnkd.in/ej7y2B7S
-
-
Biosimilars vs. Leflunomide: New study reveals a more effective and affordable option for patients with RA after methotrexate fails. What does this mean for you? Find out more: https://lnkd.in/eTe-73P4
-
-
Sarfaraz K. Niazi, PhD, has long discussed the challenges with PBMs that plague the biosimilar industry. Join us as he addresses the NYT article where the FTC exposes the middlemen keeping you from more affordable medications and the new legislation that attempts to reform their practices and encourage biosimilar adoption. https://lnkd.in/eJaJ929c
-